Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Payables (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Payables data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Payables rose 45.66% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, up 45.66%, while the annual FY2024 figure was $946259.0, 28.26% down from the prior year.
  • Payables reached $1.6 million in Q3 2025 per GANX's latest filing, down from $2.7 million in the prior quarter.
  • Across five years, Payables topped out at $2.7 million in Q2 2025 and bottomed at $560479.0 in Q4 2021.
  • Average Payables over 5 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 41.71% in 2021, then surged 190.13% in 2022.
  • A 5-year view of Payables shows it stood at $560479.0 in 2021, then soared by 190.13% to $1.6 million in 2022, then dropped by 18.89% to $1.3 million in 2023, then decreased by 28.26% to $946259.0 in 2024, then soared by 69.09% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.6 million in Q3 2025, $2.7 million in Q2 2025, and $2.2 million in Q1 2025.